Related to Phase III Data Shows Novartis’ Canakinumab Enables SJIA Patients to Remain Symptom Free

• Novartis and HGS Ditch HCV Drug as EMEA and FDA Express Risk-Benefit Concerns
  
• Novartis Teams with Synthetic Genomics Vaccines to Develop Flu Seed Virus Banks
  
• Novartis Inks U.S. Commercialization Deal for Cepheid’s Ph+ CML Prognostic Tool
  
• Pivotal Study Finds Novartis Adjuvanted Flu Vaccine 89% Effective in Infants and Children
  
• sBLA Filing for Novartis' Menveo Vaccine in Infants Imminent after Positive Phase III Data
  
• Novartis’ Afinitor Cleared by FDA for Treating SEGA Tumors in Tuberous Sclerosis
  
• Novartis Pays Incyte $50M on Start of Phase III Trial with INCB18424 for Polycythemia Vera
  
• Antisoma and Novartis Ditch ASA404 After Second Phase III NSCLC Trial Bombs
  
• IP-K Extends Collaborations with Sanofi-Aventis R&D and Novartis Tropical Disease Institute
  
• Asuragen and Novartis to Facilitate Standardization of BCR-ABL1 RT-qPCR Results
  
• Novartis Withdraws U.S. and EU sNDAs for Zometa in Breast Cancer
  
• U.S. Army Awards CHLA $1.05M for Next-Gen Sequencing Facility for Childhood Diseases
  
• Novartis Snags Remaining 23% Stake in Alcon with $12.9B Cash and Share Deal
  
• Novartis to Build Manufacturing Plant in St. Petersburg as Part of $500M Russian Commitment
  
• Novartis Plans Filing for Myelofibrosis Candidate in Light of Positive Phase III Data
  
• Japan Clears Novartis’ Tasigna for First-Line Treatment of Ph+ CML
  
• FDA Clears Novartis’ Amturnide Triple Combination Hypertension Drug
  
• EC Clears Novartis’ Lucentis for Diabetic Macular Edema
  
• Novartis Wins Positive Recommendation for Its MS Drug from CHMP
  
• Novartis to Buy Personalized Diagnostics Services Firm Genoptix for $470M